Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY23 Earnings Presentation
25 slides from Dishman Carbogen Amcis's earnings presentation, Aug 9, 2022
Slide 1: Dishman Carbogen Amcis filing cover letter
Dishman Carbogen AmcK Dishman Carbogen Amcis Ltd Dishman Corporate House lscon-Bopal Road, Ambli, Ahmedabad - 380058 Gujarat, India CIN:L74900GJ2007PLC051338 +91 27 1742 0102 � dishman@dishmangroup.com B www.imdcal.com 1$ 9th August, 2022 To, To, Department of Corporate Services The Manager, BSE Ltd
Slide 2: Quarter ended June 30th, 2022
Quarter ended June 30th, 2022 August 2022
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) 21,407 EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 16,948 4,976 3,400 4,453 3,937 2,538 26.8% 24.3% 2,744 18.4% 26.3% 14.3% FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22^ FY18 FY19
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
Dishman Carbogen Amcis QUARTER
Slide 8: Q1 FY23 Result Highlights
Q1 FY23 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,507 5,690 5,406 1,006 843 904 18.3% 14.8% 16.7% Q1FY22 Q4FY22 Q1FY23 Q1FY22 Q4FY22^ Q1FY23 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 8.4% 5.5 461 4.0% 4.5 4.5 2.0% 872 218 702 693 113 Q1FY22 Q4FY22
Slide 9: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q1 FY23 Q1 FY22 YoY % Q4 FY22 QoQ% FY22 Income from Operations (Net) 5,406.1 5,507.3 -1.8% 5,689.9 -5.0% 21,406.9 COGS 919.9 1,284.7 -28.4% 1,477.2 -37.7% 4,474.2 Employee Expenses 2,563.8 2,390.3 7.3% 2,525.9 1.5% 9,814.9 Other Expenses 1,039.4 825.9 25
Slide 10: Revenue Breakup Analysis
REVENUE BREAKUP ANALYSIS Revenues (₹ mn) Q1 FY23 Q1 FY22 YoY % Q4 FY22 QoQ% FY22 DCAL India - NCE APIs & Intermediates1 622.5 324.4 91.9% 484.7 28.4% 1,596.8 DCAL India - Quats & Generics1 514.1 479.9 7.1% 573.4 -10.3% 1,852.0 CARBOGEN AMCIS - Contract Research & 3,634.9 3,528.4 3.0% 3,999.6 -9.1% 1
Slide 11: Revenue Break-up
REVENUE BREAK-UP Total Operating Revenue – Q1 FY22 Total Operating Revenue – Q1 FY23 DCAL India - NCE APIs & Intermediates 11.5% 11.7% 21.3% 5.9% DCAL India - Quats & 8.7% 9.5% Generics CARBOGEN AMCIS - Contract Research & Manufacturing Services 64.1% 67.2% CARBOGEN AMCIS - Cholesterol & Vit D Analo
Slide 12: Margin Analysis
MARGIN ANALYSIS EBITDA Margin % Q1 FY23 Q1 FY22 Q4 FY22 FY22 DCAL India - NCE APIs & Intermediates1 3.5% - - - DCAL India - Quats & Generics1 10.4% 5.5% 7.2% 7.0% CARBOGEN AMCIS - Contract Research & 19.4% 18.1% 14.6% 18.2% Manufacturing Services2 CARBOGEN AMCIS - Cholesterol & Vit D Analogues3 19.3
Slide 13: Q1 FY23 Result Highlights
Q1 FY23 RESULT HIGHLIGHTS Net Revenue at Rs 5,406.1 mn in Q1 FY23 down by 1.8% YoY mainly on account of lower revenues from Netherlands business. Dishman Carbogen Amcis – NCE APIs and Intermediates revenue increased by 91.9% YoY primarily due to: Increased supplies of APIs and intermediates from Bav
Slide 14: Company Overview
Dishman Carbogen Amcis COMPANY
Slide 15: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 16: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 17: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 18: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 19: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 20: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 21: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY22 FY22 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 20
Slide 22: Industry Overview
Dishman Carbogen Amcis INDUSTRY
Slide 23: Top 20 Therapy Areas (US$ bn) - 2026
2026 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2026 5-Yr CAGR 2021-2025 Oncologics 306 9-12% Immunology 178 6-9% Antidiabetics 173 Top 20 Therapy Areas (US$ bn) - 2026 6-9% Neurology 151 3-6% Cardiovascular 87 4-7% Antic
Slide 24: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 23 Sourc
Slide 25: For Further Queries
FOR FURTHER QUERIES Mr. Harshil Dalal Mr. Binay Sarda Global CFO Ernst & Young LLP Email: harshil.dalal@dishmangroup.com P: +91 22 6192 0000 Email: binay.sarda@in.ey.com
Dishman Carbogen Amcis — Q1 FY23 Earnings Presentation on 6ix